$40,000.00 in Sales Expected for TG Therapeutics Inc (TGTX) This Quarter

Brokerages expect TG Therapeutics Inc (NASDAQ:TGTX) to report $40,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 during the same quarter last year. The company is scheduled to issue its next quarterly earnings report on Friday, March 9th.

On average, analysts expect that TG Therapeutics will report full-year sales of $40,000.00 for the current fiscal year, with estimates ranging from $150,000.00 to $200,000.00. For the next year, analysts expect that the firm will post sales of $150,000.00 per share, with estimates ranging from $150,000.00 to $160,000.00. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million.

Several equities analysts recently commented on the stock. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. B. Riley reaffirmed a “buy” rating and issued a $21.50 price objective on shares of TG Therapeutics in a research report on Wednesday, January 17th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research report on Tuesday, January 16th. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.50.

In other TG Therapeutics news, CFO Sean A. Power sold 32,006 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 16.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of TGTX. Legal & General Group Plc raised its position in TG Therapeutics by 14.9% during the 2nd quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,463 shares during the last quarter. First Mercantile Trust Co. raised its position in TG Therapeutics by 28.6% during the 4th quarter. First Mercantile Trust Co. now owns 26,701 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 5,938 shares during the last quarter. Voya Investment Management LLC raised its position in TG Therapeutics by 40.2% during the 2nd quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 6,463 shares during the last quarter. CIBC World Markets Inc. purchased a new position in TG Therapeutics during the 4th quarter worth approximately $250,000. Finally, Nationwide Fund Advisors raised its position in TG Therapeutics by 24.2% during the 2nd quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 5,167 shares during the last quarter. 48.73% of the stock is owned by institutional investors.

TG Therapeutics (NASDAQ:TGTX) opened at $12.00 on Tuesday. The company has a market cap of $847.83, a P/E ratio of -6.22 and a beta of 1.67. TG Therapeutics has a 1 year low of $4.50 and a 1 year high of $15.35.

COPYRIGHT VIOLATION WARNING: “$40,000.00 in Sales Expected for TG Therapeutics Inc (TGTX) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/06/40000-00-in-sales-expected-for-tg-therapeutics-inc-tgtx-this-quarter.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply